Morgan Stanley Affimed N.V. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.32 - $0.62 $458,449 - $888,245	1,432,654 New	1,432,654 $888,000
Q4 2023 Feb 13, 2024	BUY	$0.32 - $0.62 $122,036 - $236,445	381,364 Added 36.28%	1,432,654 $888,000
Q3 2023 Nov 15, 2023	BUY	$0.46 - $0.65 $149,057 - $210,625	324,039 Added 44.56%	1,051,290 $504,000
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $97,992 - $185,670	171,917 Added 30.96%	727,251 $436,000
Q1 2023 May 15, 2023	SELL	$0.66 - $1.29 $1.03 Million - $2 Million	-1,554,137 Reduced 73.67%	555,334 $416,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $1.8 Million - $4.01 Million	1,635,580 Added 345.14%	2,109,471 $2.62 Million
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $40,142 - $67,996	-20,481 Reduced 4.14%	473,891 $976,000
Q2 2022 Oct 27, 2022	BUY	$2.27 - $4.86 $771,961 - $1.65 Million	340,071 Added 220.39%	494,372 $1.37 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $771,961 - $1.65 Million	340,071 Added 220.39%	494,372 $1.37 Million
Q1 2022 Oct 27, 2022	SELL	$3.69 - $5.65 $1.25 Million - $1.92 Million	-340,071 Reduced 68.79%	154,301 $674,000
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $415,988 - $636,947	-112,734 Reduced 42.22%	154,301 $674,000
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $3.07 Million - $4.05 Million	-572,265 Reduced 68.18%	267,035 $1.47 Million
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $4.65 Million - $6.3 Million	839,300 New	839,300 $5.19 Million

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $178M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.